Technology | EP Mapping and Imaging Systems | April 26, 2019

Acutus Medical Receives FDA Clearance for Second-generation AcQMap Platform

Company also announces CE Mark approval in Europe for AcQMap contact mapping software

Acutus Medical Receives FDA Clearance for Second-generation AcQMap Platform

April 26, 2019 — Acutus Medical announced U.S. Food and Drug Administration (FDA) clearance of its second-generation AcQMap platform, along with CE Mark approval for its AcQMap contact mapping software.

AcQMap offers expanded functionality that provides physicians with more options to inform individualized patient therapy. All AcQMap systems retain the ability to quickly reconstruct atrial anatomy using ultrasound and map electrical patterns using non-contact, charge density technology, creating ultra-high-resolution 3-D images in real time.

"The contact mapping speed with the new Acutus system was extremely fast, which made it very easy to use," said Christian Meyer, M.D., University Medical Center Hamburg-Eppendorf, Hamburg, Germany. "Clinically, having this capability available on one system that also does non-contact mapping allows me to do exactly what makes sense case by case. For routine cases, my treatment strategy can be confirmed using conventional mapping catheters. In more complex cases, such as atrial fibrillation, I can gather more comprehensive data about each patient's anatomy and arrhythmia in real time with the non-contact charge density catheter, making AcQMap the complete atrial mapping solution."

Cardiac ablation treatment can improve quality of life for patients with atrial arrhythmias such as atrial fibrillation (AF). AF affects more than 33 million people globally, and increases the risk of stroke and heart failure.1,2 AcQMap enables physicians to uncover the electrical activation pattern of the heart with real-time visualization during electrophysiology procedures. With non-contact mapping, physicians see full-chamber, continuous beat-by-beat arrhythmia conduction and can locate arrhythmias outside the pulmonary veins to inform their treatment strategy, enabling an iterative map-ablate-remap approach.

Acutus Medical's contact mapping software is compatible with both first- and second-generation AcQMap platforms and will be installed on all European systems in Q3 2019. The second-generation AcQMap system is built to support future software innovations and will be available in the U.S. in Q3 2019.

For more information: www.acutusmedical.com

References

1. Staerk L, Sherer JA, Ko D, et al. Atrial Fibrillation. Circ Res 2017;120:1501-17. DOI: 10.1161/CIRCRESAHA.117.309732.

2. Chugh, S.S., Havmoeller, R., Narayanan, K. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circ Feb 25. 2014; 129: 837–847. DOI: 10.1161/CIRCULATIONAHA.113.005119.


Related Content

News

Feb. 6, 2026 — Abbott has announced new clinical data from two late-breaking presentations at AF Symposium in Boston ...

Home February 06, 2026
Home
News

Jan. 20, 2026 — Abbott has received CE Mark in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat ...

Home January 22, 2026
Home
News

Jan. 20, 2026 — Kardium Inc. has announced the publication of the PULSAR clinical trial results in the Journal of the ...

Home January 21, 2026
Home
Feature | Kyle Hardner

Robotic Magnetic Navigation (RMN) emerged two decades ago as an alternative approach to performing complex ablation ...

Home January 09, 2026
Home
News

Jan. 6, 2026 — Stereotaxis, a supplier of surgical robotics for minimally invasive endovascular intervention, has ...

Home January 06, 2026
Home
News

Oct. 10, 2025 — Johnson & Johnson MedTech, in collaboration with the Heart Rhythm Clinical and Research Solutions, LLC ...

Home October 13, 2025
Home
News

Sept. 2, 2025 — Johnson & Johnson MedTech has announced acute safety and effectiveness results from the Varipure ...

Home September 05, 2025
Home
News

Sept. 3, 2025 — Kardium Inc. recently announced it has received pre-market approval (PMA) for the Globe Pulsed Field ...

Home September 03, 2025
Home
News

July 14, 2025  –  Johnson & Johnson MedTech has announced U.S. Food and Drug Administration (FDA) approval of an update ...

Home July 14, 2025
Home
News

July 7, 2025 — Catheter ablation is a minimally invasive treatment for abnormal heart rhythms. It is often successful in ...

Home July 09, 2025
Home
Subscribe Now